# Efficacy and Safety of Teicoplanin in CDAD

> **NCT04003818** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 50 (actual)

## Conditions studied

- Clostridium Difficile Infection-associated Diarrhea and Colitis

## Interventions

- **DRUG:** TEICOPLANIN

## Key facts

- **NCT ID:** NCT04003818
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-15
- **Primary completion:** 2021-01-21
- **Final completion:** 2021-03-10
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Due to COVID-19 and great challenges during patient enrolment period, current status of this study is far behind the plan. The study cannot be completed according to the plan. Sanofi decides to terminate the study upon comprehensive assessment.
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003818, "Efficacy and Safety of Teicoplanin in CDAD". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04003818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*